Rapid Micro Biosystems Inc. (RPID) stock soared to a 52-week high, reaching $1.48 USD, marking a significant milestone for the company. According to InvestingPro data, the stock has demonstrated remarkable momentum with a 115% surge over the past six months and a robust 17.5% gain in just the last week. This peak reflects a robust year-over-year growth, with the stock experiencing an impressive 44.81% increase in value over the past year. Investors have shown increased confidence in Rapid Micro Biosystems’ potential, as the company continues to make strides in its sector, leading to heightened trading activity and investor interest surrounding the stock’s performance. Technical indicators available on InvestingPro suggest the stock is currently in overbought territory, with 12 additional ProTips available to help investors make informed decisions.
In other recent news, Rapid Micro Biosystems announced record revenue growth for the fourth quarter of 2024, expecting a revenue of approximately $8.2 million, marking a 30% growth compared to the prior year. The full-year revenue for 2024 is anticipated to be around $28.1 million, representing an increase of about 25% from the previous year. The company also reported a successful collaboration with Lonza, a global leader in life sciences, leading to the creation of a fully automated end-to-end environmental monitoring quality control solution.
In the third quarter of the same year, Rapid Micro Biosystems reported a record total revenue of $7.6 million, a 24% year-over-year increase. This marked the eighth consecutive quarter the company has surpassed its guidance. Despite these financial strides, the company still operates at a net loss, with Q3 2024’s loss recorded at $11.3 million.
These recent developments, including a multi-system order from a top 20 pharma customer and strong prospects in the biologics and cell and gene consumables sectors, point towards a path of sustainable growth for Rapid Micro Biosystems.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.